Your SlideShare is downloading. ×
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
BTSI150.doc
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

BTSI150.doc

312

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
312
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  1. THE U.S. MARKET FOR DIAGNOSTIC RADIOPHAMACEUTICALS TABLE OF CONTENTS Section Page 1.0 MARKET STATUS, TRENDS AND FORECASTS 1-1 1.1 INTRODUCTION AND OVERVIEW 1-1 1.1.1 Interdependence of Diagnostic and Therapeutic Products 1-2 1.1.2 Developments in Cardiology and Neurology 1-4 1.1.3 Rapid Growth in PET Procedures 1-5 1.1.4 Comparative Markets for Diagnostic and Therapeutic Products 1-6 1.2 MARKET ENVIRONMENT 1-6 1.2.1 New Products for Cardiology 1-11 1.2.2 New Diagnostic and Therapeutic Products for Oncology 1-13 1.3 RADIOPHARMACEUTICAL MARKET OVERVIEW 1-16 1.3.1 Current Market Overview 1-17 1.3.2 Summary Forecasts for Diagnostic Radiopharmaceuticals 1-20 1.4 DIAGNOSTIC PRODUCT SALES AND MARKET FORECASTS 1-20 1.4.1 Nuclear Cardiology Procedures And Product Sales 1-30 1.4.2 Heart Perfusion Studies 1-35 1.4.3 Cardiology PET Studies with the Rubidium Generator 1-38 1.4.4 Blood Pool Studies 1-39 1.4.5 Pharmacologic Stress Studies 1-39 TABLE OF CONTENTS ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. i Report 150
  2. Section Page 1.4.6 Myocardial Viability and Thrombus Imaging 1-40 1.4.6.1 CardioVision 1-45 1.4.6.2 BMIPP and Fatty Acid Metabolism 1-46 1.4.6.3 AmiScan (Technetium-Glucarate) 1-47 1.4.6.4 Myocardial Studies with Apomate 1-48 1.4.6.5 Myocardial Viability Studies with FDG 1-49 1.4.6.6 Thrombus and Vascular Imaging 1-49 1.5 GENERAL NUCLEAR MEDICINE PRODUCTS 1-50 1.5.1 Technetium Products and Kits 1-54 1.5.2 Other Diagnostic Isotope Products 1-58 1.5.3 Changes in Market Activity for Primary Nuclear Studies 1-58 1.5.3.1 Bone Scans 1-60 1.5.3.2 Lung Studies 1-60 1.5.3.3 Thyroid Studies 1-62 1.5.3.4 Kidney Studies 1-63 1.5.3.5 Liver Studies 1-64 1.5.3.6 Gall Bladder Studies 1-64 1.5.3.7 Brain Studies 1-65 1.5.3.8 White Blood Cell Labeling and Infection Imaging 1-66 1.5.3.9 Other Nuclear Medicine Procedures 1-67 1.5.4 New In Vivo Infection Imaging Agents 1-67 TABLE OF CONTENTS Section Page ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. ii Report 150
  3. 1.6 TARGETED ONCOLOGY IMAGING AGENTS 1-68 1.6.1 FDG Imaging for Oncology 1-71 1.6.2 Oncology Imaging with Targeted Antibodies and Peptides 1-72 1.7 COMMERCIAL RADIOPHARMACIES 1-74 1.7.1 Sales Distribution of Radiopharmacy Companies 1-77 1.7.2 Effect of the Syncor-DuPont Alignment 1-78 1.7.3 Radiopharmacy Material Costs and Gross Margins 1-79 1.7.4 Pricing Strategies and Regional Competition 1-80 2.0 RADIOPHARMACEUTICAL PRODUCTS AND TECHNOLOGY 2-1 2.1 TYPES OF RADIOP0HARMACEUTICAL PRODUCTS 2-1 2.2 FUNCTIONAL CHARACTERISTICS 2-5 2.2.1 Radiopharmaceutical Selection 2-7 2.3 RADIOISOTOPE PRODUCTION METHODS 2-10 2.3.1 Nuclear Reactors 2-11 2.3.2 Accelerators 2-14 2.3.3 Radionuclide Generators 2-15 2.4 RADIOPHARMACEUTICAL PREPARATION 2-16 2.4.1 Commercial Radiopharmacies 2-17 2.4.2 New Radiopharmaceuticals 2-18 3.0 CLINICAL APPLICATIONS 3-1 3.1 TYPES OF NUCLEAR MEDICINE PROCEDURES 3-1 TABLE OF CONTENTS Section Page 3.2 NUCLEAR CARDIOLOGY 3-7 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. iii Report 150
  4. 3.2.1 Myocardial Perfusion 3-8 3.2.1.1 Thallium 3-8 3.2.1.2 Cardiolite and Myoview 3-8 3.2.2 Stress Testing 3-9 3.2.3 Cardiac Function Studies 3-11 3.2.4 First-Pass Heart Studies 3-12 3.3 OPTIONS IN RADIOPHARMACEUTICAL SELECTION 3-13 3.3.1 Technetium-Labeled Myocardial Agents 3-13 3.3.2 Clinical Protocols 3-14 3.3.2.1 Cardiolite and Myoview Imaging 3-14 3.3.2.2 Dual Isotope Studies 3-16 3.3.2.3 Pharmacologic Stressors 3-17 3.4 OTHER ORGAN STUDIES 3-18 3.4.1 Bone Imaging 3-18 3.4.2 Liver Studies 3-19 3.3.3 Thyroid Studies 3-20 3.4.4 Brain Studies 3-20 3.4.5 Lung Perfusion 3-21 3.5 PET CLINICAL APPLICATIONS 3-23 3.5.1 Neurological Applications 3-23 TABLE OF CONTENTS Section Page 3.5.2 Stroke and Cerebrovascular Disease 3-24 3.5.3 Cancer Management and Tumor Evaluation 3-26 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. iv Report 150
  5. 3.5.4 Cardiac Applications 3-26 4.0 CURRENT DEVELOPMENTS AND EMERGING TECHNOLOGY 4-1 4.1 NEW TECHNOLOGY OVERVIEW 4-1 4.2 NUCLEAR CARDIOLOGY AND MYOCARDIAL VIABILITY 4-2 4.2.1 Technetium-NOET for Cardiac Perfusion 4-4 4.2.2 Myocardial Viability Imaging 4-5 4.2.3 CardioVision (ERFA-SA, Belgium) 4-6 4.2.4 I-123 BMIPP (Biostream, Inc) 4-8 4.2.5 AmiScan-Technetium Glucarate (Draximage) 4-9 4.2.6 Apomate-Recombinant Annexin (Theseus Imaging Corp.) 4-10 4.2.7 Thrombus Detection 4-12 4.3 IMAGING INFECTION AND INFLAMMATION 4-14 4.3.1 LeuTech (Palatin Technologies) 4-15 4.3.2 Leukoscan (Immunomedics) 4-18 4.3.3 P483H Peptide for Imaging Inflammation (Diatide/Berlex) 4-19 4.3.4 Infecton (Draximage) 4-20 4.3.5 RP128 (Bracco) 4-20 4.4 NEW NEUROLOGICAL IMAGING AGENTS 4-21 4.4.1 Products for Imaging Dopamine Activity in the Brain 4-23 TABLE OF CONTENTS Section Page 4.4.2 I-123 Altropane (Boston Life Sciences) 4-24 4.4.3 I-123 ß-CIT (Dopascan) 4-25 4.4.4 DATscan (Flouro Propyl ß-CIT) 4-26 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. v Report 150
  6. 4.4.5 Technetium-Trodat 4-28 4.4.6 New Technetium Analogs of Altropane 4-29 4.5 CANCER IMAGING WITH ANTIBODIES AND PEPTIDES 4-30 4.5.1 Products for Imaging Prostate Cancer 4-32 4.5.2 Imaging of Somatostatin Tumors and Lung Cancer 4-35 4.5.3 Expanded Indications for CEA-Scan (Immunomedics) 4-37 4.5.4 CEA-Scan for Intraoperative Scanning 4-39 4.5.5 Other Immunomedics’ Diagnostic Products 4-40 4.5.6 Vitamin B-12-Based Imaging (Copharos, Inc) 4-41 5.0 INDUSTRY ANALYSIS 5-1 5.1 INDUSTRY OVERVIEW AND TRENDS 5-1 5.2 INDUSTRY ENVIRONMENT 5-3 5.2.1 Market Orientation 5-4 5.2.2 Market Concentration 5-5 5.2.3 Industry Pricing 5-6 5.3 INDUSTRY ANALYSIS BY PRODUCT CATEGORY 5-7 5.3.1 Market Overview 5-9 5.3.2 Market Distribution 5-10 TABLE OF CONTENTS10 Section Page 5.3.3 Product Orientation of the Major Companies 5-10 5.3.4 Changes in Market Share of the Major Companies 5-15 5.3.5 Projections for New Products 5-15 5.3.6 Market Segments 5-16 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. vi Report 150
  7. 5.4 NUCLEAR CARDIOLOGY PRODUCTS 5-17 5.4.1 Thallium 5-17 5.4.2 Cardiolite 5-20 5.4.3 Myoview 5-22 5.4.4 Cardiogen 5-22 5.4.5 Pharmacologic Stress Agents 5-26 5.4.6 Technetium Pyrophosphate (PYP) for Cardiac Performance 5-29 5.5 GENERAL NUCLEAR MEDICINE PRODUCTS 5-32 5.5.1 Technetium Generators 5-32 5.5.2 Technetium MDP Kits for Bone Imaging 5-34 5.5.3 Technetium DTPA Kits for Kidney and Brain Scans 5-36 5.5.4 Technetium Sulfur Colloid Kits 5-38 5.5.5 Technetium Aggregated Albumin for Lung Scans 5-40 5.5.6 Technetium Biliary Agents for Gall Bladder Studies 5-40 5.5.7 Technescan MAG-3 for Kidney Function 5-42 5.5.8 Iodine Products 5-45 5.5.9 Brain Imaging Agents 5-49 TABLE OF CONTENTS Section Page 5.5.10 Gallium for Tumors, Abscesses and Inflammation 5-53 5.5.11 Xenon for Lung Ventilation Studies 5-53 5.5.12 Indium Oxine for Blood Cell Labeling 5-56 5.6 SPECIALIZED ONCOLOGY PRODUCTS 5-58 5.6.1 ProstaScint for Imaging Prostate Cancer 5-58 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. vii Report 150
  8. 5.6.2 OncoScint for Imaging Colorectal and Ovarian Cancer 5-60 5.6.3 CEA Scan for Imaging Colorectal Cancer 5-62 5.6.4 Octreoscan for Imaging Neuroendocrine Tumors 5-65 5.6.5 NeoTect for Detection of Lung Cancer 5-67 5.6.6 Indium Chloride as a Radiolabel for Cancer Imaging 5-68 5.6.7 FDG for Metabolic Imaging 5-70 6.0 END-USER ANALYSIS 6-1 6.1 OVERVIEW OF THE USER ENVIRONMENT 6-1 6.1.1 Organization of Nuclear Medicine Departments 6-2 6.2 ALLOCATION OF HOSPITAL NUCLEAR MEDICINE EQUIPMENT 6-3 6.3 COMPARATIVE UTILIZATION PARAMETERS 6-3 6.4 DISTRIBUTION OF IMAGING PROCEDURES 6-5 6.4.1 Relative Diagnostic Activity 6-7 6.4.2 Relative Procedure Volume 6-7 6.4.3 Imaging Activity Index 6-9 6.4.4 Distribution of Nuclear Studies in Hospitals & Clinics 6-11 TABLE OF CONTENTS Section Page 6.5 THE IN-HOSPITAL HOT LAB VS. COMMERCIAL PHARMACIES 6-11 6.5.1 Unit-Dose Packaging 6-14 6.5.2 Pricing Practices 6-15 6.6 NONHOSPITAL END-USERS 6-17 6.7 ISSUES OF BOARD CERTIFICATION 6-18 7.0 COMPANY PROFILES 7-1 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. viii Report 150
  9. 7.1 INTRODUCTION 7-1 7.2 AMERSHAM HEALTH 7-3 7.3 ANTISOMA, LTD. (UK) 7-10 7.4 BERLEX LABORATORIES INC. 7-11 7.5 CIS BiO-INTERNATIONAL (Berlex) 7-14 7.6 DIATIDE RESEARCH LABORATORIES (Berlex) 7-16 7.7 BEST MEDICAL INTERNATIONAL INC. 7-19 7.8 BIOSTREAM, INC. 7-19 7.9 BOSTON LIFE SCIENCES, INC. 7-21 7.10 BRACCO DIAGNOSTICS 7-24 7.11 C.R. BARD 7-26 7.12 COPHAROS, INC. 7-27 7.13 CORDIS DIVISIO N OF J&J 7-30 7.14 CORIXA CORPORATION 7-32 7.15 CYTOGEN CORPORATION 7-36 TABLE OF CONTENTS Section Page 7.16 DOW CHEMICAL CO. 7-41 7.17 DRAXIMAGE, INC. 7-42 7.18 DUPONT BMS (BRISTOL MYERS SQUIBB). 7-45 7.19 FUJISAWA USA INC. 7-47 7.20 GUIDANT CORPORATION 7-48 7.21 IDEC PHARMACEUTICALS CORPORATION 7-50 7.22 IMAGYN MEDICAL TECHNOLOGIES 7-54 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. ix Report 150
  10. 7.23 IMMUNOMEDICS, INC. 7-56 7.24 LYNNTECH, INC. 7-60 7.25 MALLINCKRODT INC. (TYCO HEALTHCARE) 7-63 7.26 MDS NORDION 7-66 7.27 MENTOR CORPORATION 7-69 7.28 NEORX CORPORATION 7-72 7.29 NORTH AMERICAN SCIENTIFIC, INC. 7-74 7.30 NOVOSTE CORPORATION 7-79 7.31 PALATIN TECHNOLOGIES INC. 7-81 7.32 PEREGRINE PHARMACEUTICALS INC. 7-85 7.33 PETNet PHARMACEUTICALS, INC. 7-87 7.34 PROXIMA THERAPEUTICS INC. 7-88 7.35 SIRTEX MEDICAL LTD. 7-90 7.36 SYNCOR INTERNATIONAL (Cardinal Health) 7-96 TABLE OF CONTENTS Section Page 7.37 THERAGENICS CORPORATION 7-98 7.38 VITA MEDICAL (Australian) 7-101 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. x Report 150
  11. THE U.S. MARKET FOR DIAGNOSTIC RADIOPHAMACEUTICALS LIST OF EXHIBITS Exhibit Page 1-1 HISTORICAL AND FORECAST GROWTH OF RADIOPHARMA- 1-7 CEUTICAL SALES FROM 1997-2008 (Graph) 1-2 COMPARATIVE SALES GROWTH OF DIAGNOSTIC AND 1-8 THERAPEUTICRADIOPHARMACEUTICALS AND BRACHYTHERAPY PRODUCTS FROM 1997-2008 1-3 COMPARATIVE SALES GROWTH OF DIAGNOSTIC AND 1-9 THERAPEUTIC RADIOPHARMACEUTICALS AND BRACHYTHERAPY FROM 1997-2008 (Graph) 1-4 HISTORIC AND FORECAST SALES GROWTH OF DIAGNOSTIC 1-18 RADIOPHARMACEUTICALS BY PRODUCT GROUP FROM 1997-2008 1-5 HISTORIC AND FORECAST SALES GROWTH OF DIAGNOSTIC 1-19 RADIOPHARMACEUTICALS BY PRODUCT GROUP FROM 1997-2008 (Graph) 1-6 2002 DIAGNOSTIC RADIOPHARMACEUTICAL SALES SUMMARY 1-21 BY PROCEDURE CATEGORY AND PRODUCT TYPE 1-7 2008 DIAGNOSTIC RADIOPHARMACEUTICAL SALES SUMMARY 1-25 BY PROCEDURE CATEGORY AND PRODUCT TYPE 1-8 HISTORIC AND FORECAST SALES GROWTH OF NUCLEAR 1-31 CARDIOLOGY AND VASCULAR IMAGING BY PRODUCT CATEGORY FROM 1997-2008 1-9 HISTORIC AND FORECAST SALES OF NUCLEAR CARDIOLOGY 1-32 AND VASCULAR IMAGING AGENTS BY PRODUCT GROUP FROM 1997-2008 (Graph) 1-10 RELATIONSHIP OF NUCLEAR CARDIOLOGY PROCEDURES 1-34 AND SALES TO GENERAL NUCLEAR MEDICINE FROM 1997-2008 1-11 HISTORIC AND FORECAST SALES OF CARDIAC PERFUSION AND 1-36 BLOOD POOL AGENTS BY PRODUCT CATEGORY FROM 1997-2008 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. xi Report 150
  12. LIST OF EXHIBITS Exhibit Page 1-12 HISTORIC AND FORECAST SALES OF HEART PERFUSION 1-37 AND BLOOD POOL AGENTS FROM 1997-2008 (Graph) 1-13 HISTORIC AND FORECAST SALES OF PHARMACOLOGIC 1-41 STRESSORS FOR CARDIAC IMAGING BY PRODUCT CATEGORY FROM 1997-2008 1-14 HISTORIC AND FORECAST SALES OF PHARMACOLOGIC STRESS 1-42 AGENTS FOR HEART IMAGING BY PRODUCT CATEGORY FROM 1997-2008 (Graph) 1-15 SALES OF CARDIOLOGY AGENTS FOR MYOCARDIAL VIABILITY, 1-43 THROMBUS AND VASCULAR IMAGING BY PRODUCT GROUP FROM 1997-2008 1-16 SALES GROWTH OF NEW MYOCARDIAL VIABILITY, THROMBUS 1-44 AND VASCULAR IMAGING AGENTS BY PRODUCT GROUP FROM 1997-2008 (Graph) 1-17 SALES OF GENERAL NUCLEAR MEDICINE PRODUCTS FOR 1-52 FUNCTIONAL STUDIES AND TARGETED CANCER IMAGING FROM 1997-2008 1-18 SALES OF GENERAL NUCLEAR MEDICINE PRODUCTS FOR 1-53 FUNCTIONAL STUDIES AND TARGETED IMAGING FROM 1997-2008 (Graph) 1-19 HISTORIC AND FORECAST GROWTH OF TECHNETIUM-BASED 1-55 PROCEDURES FROM 1997-2008 1-20 HISTORIC AND FORECAST SALES OF TECHNETIUM AND 1-56 TECHNETIUM KITS FOR GENERAL PURPOSE IMAGING BY PRODUCT CATEGORY FROM 1997-2008 1-21 HISTORIC AND FORECAST SALES OF ISOTOPE PRODUCTS FOR 1-59 FUNCTIONAL IMAGING, BY PRODUCT CATEGORY, FROM 1997-2008 1-22 HISTORIC AND FORECAST SALES OF FDG, ANTIBODIES AND 1-70 PEPTIDES FOR TARGETED CANCER IMAGING BY PRODUCT GROUP FROM 1997-2008 1-23 2002 SALES AND MARKET SHARES OF RADIOPHARMACY 1-75 COMPANIES AND INDEPENDENT NUCLEAR PHARMACIES ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. xii Report 150
  13. LIST OF EXHIBITS Exhibit Page 1-24 ANALYSIS OF RADIOPHARMACY REVENUES, COSTS 1-76 AND GROSS PROFIT IN 2002 1-25 2002 AVERAGE COST OF RADIOPHARMACEUTICALS FOR 1-81 NUCLEAR PHARMACIESCOMPARED WITH HOSPITALS PURCHASING DIRECT FROM MANUFACTURERS 3-1 CLINICAL INDICATIONS FOR NUCLEAR IMAGING PROCEDURES 3-3 5-1 YEAR 2002 RADIOPHARMACEUTICAL SALES SUMMARY, 5-8 MANUFACTURERS' SALES DOLLAR VOLUME AND MARKET SHARE 5-2 DISTRIBUTION OF RADIOPHARMACEUTICAL SALES IN THE U.S. 5-11 IN 2002, MANUFACTURER'S SALES DOLLAR VOLUME BY PRODUCT CATEGORY 5-3 2002 SALES OF THALLIUM FOR HEART PERFUSION STUDIES, 5-19 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-4 2002 SALES OF CARDIOLITE FOR HEART PERFUSION STUDIES, 5-21 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-5 2002 SALES OF MYOVIEW FOR HEART PERFUSION STUDIES, 5-23 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-6 2002 SALES OF CARDIOGEN, RUBIDIUM-81 GENERATOR, 5-25 FOR HEART PERFUSION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-7 2002 SALES OF PERSANTINE FOR PHARMACOLOGIC STRESS, 5-27 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-8 2002 SALES OF ADENOSINE FOR PHARMACOLOGIC STRESS, 5-28 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-9 2002 SALES OF GENERIC DIPYRIDAMOLE FOR PHARMACOLOGIC 5-30 STRESS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-10 2002 SALES OF PYP-PYROPHOSPHATE KITS FOR HEART IMAGING, 5-31 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE LIST OF EXHIBITS Exhibit Page ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. xiii Report 150
  14. 5-11 2002 SALES OF TECHNETIUM GENERATORS, 5-33 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-12 2002 SALES OF MDP AND HDP KITS FOR BONE IMAGING, 5-35 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-13 2002 SALES OF TECHNETIUM DTPA KITS FOR AEROSOL 5-37 LUNG VENTILATION, BRAIN AND KIDNEY SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-14 2002 SALES OF TECHNETIUM SULFUR COLLOID KITS FOR LIVER 5-39 SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-15 2002 SALES OF MACRO-AGGREGATED ALBUMIN FOR LUNG 5-41 PERFUSION SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-16 2002 SALES OF TECHNETIUM BILIARY AGENTS FOR GALL BLADDER 5-43 STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-17 2002 SALES OF TECHNESCAN MAG-3 FOR KIDNEY FUNCTION 5-46 STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-18 2002 SALES OF IODINE 131 FOR THYROID IMAGING AND KIDNEY 5-47 SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-19 2002 SALES OF IODINE 123 FOR THYROID SCANS, 5-48 RADIOPHARMACEUTICAL SUPPLIER, SALES DOLLAR VOLUME AND MARKET SHARE 5-20 2002 SALES OF CERETEC FOR BRAIN PERFUSION STUDIES 5-51 AND WHITE BLOOD CELL LABELING, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-21 2002 SALES OF NEUROLITE FOR BRAIN PERFUSION STUDIES, 5-52 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-22 2002 SALES OF GALLIUM FOR SCANS OF TUMORS, 5-54 ABSCESSES AND INFLAMMATION, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE LIST OF EXHIBITS Exhibit Page 5-23 2002 SALES OF XENON FOR LUNG VENTILATION STUDIES, 5-55 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. xiv Report 150
  15. 5-24 2002 SALES OF INDIUM OXINE FOR IMAGING INFLAMMATORY 5-57 PROCESSES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-25 2002 SALES OF PROSTASCINT FOR IMAGING PROSTATE CANCER, 5-59 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-26 2002 SALES OF ONCOSCINT FOR IMAGING COLORECTAL AND 5-61 OVARIAN CANCER, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-27 2002 SALES OF CEA SCAN FOR IMAGING COLORECTAL CANCER, 5-64 RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-28 2002 SALES OF OCTREOSCAN FOR IMAGING NEUROENDOCRINE 5-66 TUMORS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-29 2002 SALES OF NEOTECT FOR LUNG CANCER, RADIOPHARMA- 5-69 CEUTICAL SUPPLIER AND MARKET SHARE 5-30 2002 SALES OF INDIUM CHLORIDE FOR COMPOUNDING WITH 5-71 CANCER IMAGING AGENTS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 5-31 2002 SALES OF FDG FOR METABOLIC IMAGING IN ONCOLOGY, 5-73 NEUROLOGY AND CARDIOLOGY, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 6-1 COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIES 6-5 BY HOSPITAL BED SIZE 6-2 COMPARATIVE UTILIZATION PARAMETERS FOR DIFFERENT 6-6 IMAGING MODALITIES IN 2002 6-3 DISTRIBUTION OF SHORT-TERM HOSPITAL BEDS IN THE U.S 6-8 BY HOSPITAL BED SIZE 6-4 DISTRIBUTION OF HOSPITAL DIAGNOSTIC IMAGING PROCEDURES 6-9 IN THE U.S. BY HOSPITAL BED SIZE IN 2002 LIST OF EXHIBITS Exhibit Page 6-5 RELATIVE PROCEDURE VOLUME AMONG DIFFERENT IMAGING 6-11 MODALITIES, PERCENTAGE RELATIONSHIP BY HOSPITAL BED SIZE IN 2002 6-6 RELATIVE ACTIVITY INDEX AMONG DIFFERENT IMAGING, 6-13 ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. xv Report 150
  16. MODALITIES PROCEDURES PER BED PER YEAR BY HOSPITAL BED SIZE IN 2002 6-7 2002 DISTRIBUTION OF NUCLEAR MEDICINE PROCEDURES 6-15 IN HOSPITALS AND IMAGING CLINICS ———————————————————————————————————————–––––– Bio-Tech Systems, Inc. xvi Report 150

×